Subtype
Pancreatic Carcinoma
CI-CAN-00003562Explore in graph →
489 active trials5 approved drugs31 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003562Explore in graph →
Clinical trials
1,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (201)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02031536 | Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery | terminated | Phase 2 | 2 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01684098 | Safety and Efficacy of FalateScan (Technetium Tc 99m EC20) in Patients With Known Suspected Recurrent or Metastatic Cancer From a Solid Tumor | completed | Phase 2 | 40 | EndocyteINDUSTRY | 0 | Jun 22, 2023 | clinicaltrials |
| NCT02047513 | Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer(NEONAX) | completed | Phase 2 | 127 | AIO-Studien-gGmbHOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02042378 | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | completed | Phase 2 | 19 | pharmaand GmbHINDUSTRY | 2 | Jun 13, 2023 | clinicaltrials |
| NCT05083247 | Preoperative mFOLFIRINOX (or Gem-Nab-P) +/- Isotoxic High-dose SBRT for Borderline Resectable Pancreatic Adenocarcinoma(STEREOPAC) | recruiting | Phase 2 | 256 | Erasme University HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT02620865 | BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 2 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 15, 2023 | clinicaltrials |
| NCT02194829 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Apr 25, 2023 | clinicaltrials |
| NCT02806687 | Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer(THERGAP-02) | completed | Phase 2 | 68 | University Hospital, ToulouseOTHER | 1 | Mar 30, 2023 | clinicaltrials |
| NCT03717298 | Evaluation of Ocoxin-Viusid® in Advanced Pancreatic Adenocarcinoma | completed | Phase 2 | 30 | Catalysis SLINDUSTRY | 1 | Mar 28, 2023 | clinicaltrials |
| NCT05733000 | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors | recruiting | Phase 2 | 94 | Northwestern UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT03331562 | A SU2C Catalyst® Trial of a PD1 Inhibitor With or Without a Vitamin D Analog for the Maintenance of Pancreatic Cancer | completed | Phase 2 | 24 | Translational Genomics Research InstituteOTHER | 1 | Dec 27, 2022 | clinicaltrials |
| NCT01939665 | PANFIRE Study: Irreversible Electroporation (IRE) to Treat Locally Advanced Pancreatic Carcinoma(PANFIRE) | completed | Phase 1 / Phase 2 | 50 | Amsterdam UMC, location VUmcOTHER | 1 | Dec 20, 2022 | clinicaltrials |
| NCT05634564 | Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer | unknown | Phase 2 | 62 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Dec 5, 2022 | clinicaltrials |
| NCT05627427 | Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard Chemotherapy | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT02564146 | First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine(ALPACA) | completed | Phase 2 | 325 | AIO-Studien-gGmbHOTHER | 1 | Nov 22, 2022 | clinicaltrials |
| NCT02562716 | S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery | completed | Phase 2 | 147 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 19, 2022 | clinicaltrials |
| NCT03723915 | Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer | terminated | Phase 2 | 17 | Northwestern UniversityOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT01547260 | Lenalidomide and Gemcitabine as First-line Treatment in Patients With Pancreatic Cancer(LENAGEM) | completed | Phase 1 / Phase 2 | 34 | Maria LiljeforsOTHER | 1 | Aug 22, 2022 | clinicaltrials |
| NCT05181605 | Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors | unknown | Phase 2 / Phase 3 | 116 | Instituto de investigación e innovación biomédica de CádizOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT02839343 | Combination Chemotherapy With or Without Hypofractionated Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer | unknown | Phase 2 | 126 | Alliance for Clinical Trials in OncologyOTHER | 2 | May 24, 2022 | clinicaltrials |
| NCT02850874 | HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02178709 | A Phase II Study of Neoadjuvant FOLFIRINOX | completed | Phase 2 | 48 | Indiana UniversityOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04835402 | Electroporation Potentiated Immunotherapy in Cancer(EPIC-1) | unknown | Phase 2 | 8 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 9, 2022 | clinicaltrials |
| NCT05268692 | Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP | recruiting | Phase 2 / Phase 3 | 500 | Kochi UniversityOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT05257122 | A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic Cancer | unknown | Phase 2 | 32 | Fudan UniversityOTHER | 1 | Feb 25, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT05181865 | Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Feb 7, 2022 | clinicaltrials |
| NCT03331640 | A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy(PANTHEON) | terminated | Phase 2 | 67 | AIO-Studien-gGmbHOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT04652206 | Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.(PANTAX-Ib) | unknown | Phase 1 / Phase 2 | 18 | Scandion Oncology A/SINDUSTRY | 2 | Dec 29, 2021 | clinicaltrials |
| NCT02125136 | Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer(NEOLAP) | completed | Phase 2 | 168 | AIO-Studien-gGmbHOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT02259725 | Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | completed | Phase 2 | 3 | University of Southern CaliforniaOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT05143151 | CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer(CAR-T) | unknown | Phase 1 / Phase 2 | 10 | Shenzhen University General HospitalOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01660711 | A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma | completed | Phase 2 | 22 | Endeavor HealthOTHER | 1 | Nov 8, 2021 | clinicaltrials |
| NCT03410914 | Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy(PATCH-DP) | completed | Phase 2 | 52 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 3, 2021 | clinicaltrials |
| NCT05066802 | A Phase 2 Trial of Neoadjuvant Modified FOLFIRINOX Chemotherapy for Resectable Pancreatic Adenocarcinoma | unknown | Phase 2 | 27 | Yonsei UniversityOTHER | 1 | Oct 4, 2021 | clinicaltrials |
| NCT04718701 | Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic Cancer(ATNPA) | unknown | Phase 2 | 53 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01666730 | Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | completed | Phase 2 | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 10, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03528785 | A Study of Nal-IRI With 5-FU, Levofolinic Acid and Oxaliplatin in Patients With Resectable Pancreatic Cancer(nITRo) | unknown | Phase 2 | 67 | Centro Ricerche Cliniche di VeronaOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01676259 | A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer(PROTACT) | unknown | Phase 2 | 80 | Silenseed LtdINDUSTRY | 2 | Jul 2, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT00031694 | Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT02311361 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2021 | clinicaltrials |
| NCT04739046 | An Exploratory Trial to Evaluate Efficacy and Safety for Combination Treatment of Adenovirus Double Suicide Gene Therapy | unknown | Phase 2 | 12 | Seoul National University Bundang HospitalOTHER | 1 | Mar 17, 2021 | clinicaltrials |
| NCT01206296 | Adjuvant Intraperitoneal Gemcitabine for Resectable Pancreatic Adenocarcinoma | terminated | Phase 2 | 9 | Medstar Health Research InstituteOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03042780 | FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 27, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jun 29, 2023source: clinicaltrials